FDA Releases Draft Guidance for Generic Synthetic Peptide Drug Products

Summary

The FDA is providing a draft guidance to help companies determine when to submit an abbreviated new drug application (ANDA) for generic versions of certain synthetic peptide drugs, which are derived from recombinant deoxyribonucleic acid (rDNA) and are similar to previously approved drugs.